Species differences in metabolism of a new antiepileptic drug candidate, DSP‐0565 [2‐(2′‐fluoro[1,1′‐biphenyl]‐2‐yl)acetamide]

The metabolism and pharmacokinetics of DSP‐0565 [2‐(2′‐fluoro[1,1′‐biphenyl]‐2‐yl)acetamide], an antiepileptic drug candidate, was investigated in rats, dogs, and humans. In human hepatocytes, [14C]DSP‐0565 was primarily metabolized via amide bond hydrolysis to (2′‐fluoro[1,1′‐biphenyl]‐2‐yl)acetic...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Biopharmaceutics & drug disposition 2019-05, Vol.40 (5-6), p.165-175
Hauptverfasser:	Yahata, Masahiro, Ishii, Yuji, Nakagawa, Tetsuya, Watanabe, Takao, Bando, Kiyoko
Format:	Artikel
Sprache:	eng
Schlagworte:	Acetamides - blood Acetamides - pharmacokinetics Acetamides - urine Acetic acid Administration, Oral Adolescent Adult Animals Anticonvulsants - blood Anticonvulsants - pharmacokinetics Anticonvulsants - urine Antiepileptic agents Benzene Biphenyl Dogs Drug dosages DSP‐0565 Feces - chemistry Female Hepatocytes Hepatocytes - metabolism Humans Hydrolysis Hydroxylation Male metabolic pathway Metabolic pathways Metabolism Metabolites Middle Aged Models, Biological Oral administration Oxidation Oxidation-Reduction Pharmacokinetics Radioactivity Rats, Sprague-Dawley Scaling Scaling factors Single-Blind Method Species Species Specificity Urine Young Adult
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!